Ranexa MERLIN study complete
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
CV Therapeutics expects top-line data from its MERLIN study of Ranexa (ranolazine) in the first quarter of 2007. The firm announced Sept. 26 that MERLIN (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes) is complete and will soon move to the close-out phase. MERLIN was designed under a special protocol assessment with FDA; the agreement stipulates that if the primary endpoint of time to first occurrence of any element of a composite endpoint is met, Ranexa could potentially be approved for treatment of ACS and secondary prevention. CVT has also said it believes MERLIN would support a labeling expansion to first-line angina (1Pharmaceutical Approvals Monthly May 2005, p. 10)...
You may also be interested in...
Ranexa Angina Reduction Enough For Restricted Indication, CVT Says
A mean weekly reduction of 0.4 angina attacks seen in the ERICA study with CV Therapeutics' Ranexa (ranolazine) is adequate for approval, the company said, despite being less than half the expected decrease
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.